

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Rilpivirine hydrochloride

March 17, 2026

Therapeutic category

Anti-virus agents

Non-proprietary name

Rilpivirine hydrochloride

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision							
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving rifampicin, carbamazepine, phenobarbital, phenytoin, phenytoin/phenobarbital, fosphenytoin, dexamethasone (systemic administration) (excluding single administration), food containing St. John's Wort, or proton pump inhibitors (omeprazole, lansoprazole, aspirin/lansoprazole, rabeprazole, esomeprazole, vonoprazan fumarate, aspirin/vonoprazan fumarate)</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p>(N/A)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving rifampicin, carbamazepine, phenobarbital, phenytoin, phenytoin/phenobarbital, fosphenytoin, <u>apalutamide</u>, <u>enzalutamide</u>, dexamethasone (systemic administration) (excluding single administration), food containing St. John's Wort, or proton pump inhibitors (omeprazole, lansoprazole, aspirin/lansoprazole, rabeprazole, esomeprazole, vonoprazan fumarate, aspirin/vonoprazan fumarate)</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="1133 970 1984 1356"> <thead> <tr> <th data-bbox="1133 970 1375 1066">Drugs</th> <th data-bbox="1379 970 1693 1066">Signs, symptoms, and treatment</th> <th data-bbox="1697 970 1984 1066">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1133 1069 1375 1356"> <p><u>Apalutamide</u></p> <p><u>Enzalutamide</u></p> </td> <td data-bbox="1379 1069 1693 1356"> <p><u>The blood concentration of rilpivirine hydrochloride may decrease, leading to attenuation of the effects of rilpivirine.</u></p> </td> <td data-bbox="1697 1069 1984 1356"> <p><u>The CYP3A-inducing activity of these drugs promotes the metabolism of rilpivirine hydrochloride.</u></p> </td> </tr> </tbody> </table>		Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<p><u>Apalutamide</u></p> <p><u>Enzalutamide</u></p>	<p><u>The blood concentration of rilpivirine hydrochloride may decrease, leading to attenuation of the effects of rilpivirine.</u></p>	<p><u>The CYP3A-inducing activity of these drugs promotes the metabolism of rilpivirine hydrochloride.</u></p>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors						
<p><u>Apalutamide</u></p> <p><u>Enzalutamide</u></p>	<p><u>The blood concentration of rilpivirine hydrochloride may decrease, leading to attenuation of the effects of rilpivirine.</u></p>	<p><u>The CYP3A-inducing activity of these drugs promotes the metabolism of rilpivirine hydrochloride.</u></p>						

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.